Critical Role for the 310 Helix Region of p57Kip2 in Cyclin-dependent Kinase 2 Inhibition and Growth Suppression*

Although crystal structural analysis of cyclin A/cyclin-dependent kinase 2 (Cdk2)/p27 (Russo, A. A., Jeffrey, P. D., Pattern, A. K., Massague, J., and Pavletich, N. P. (1996) Nature 382, 325–331) has suggested that the 310 helix region in Cdk inhibitors of the Cip/Kip family may be involved in the inhibition of cyclin/Cdk activities, there is no biochemical evidence supporting this hypothesis. In the present study, we demonstrated that cyclin and Cdk binding domains of p57 were necessary but were not sufficient in themselves for the inhibition of cyclin A/Cdk2 and cyclin E/Cdk2, and that the 310 helix region of this protein is indispensable for the inhibition of these complexes. In contrast, the 310 helix regions of p21 and p27 were not required, and cyclin- and Cdk-binding domains alone were sufficient for the inhibition of all cyclin/Cdk complexes examined. Site-directed mutagenesis identified phenylalanine 79 and tyrosine 80 within the 310 helix region of p57 as crucial residues for kinase inhibition, supporting the structural evidence that the 310 helix binds deep inside the catalytic cleft of Cdk2, mimicking ATP. Mutations within the 310helix region of the p57 molecule completely abolished the ability to arrest the cell cycle at G1 in vivo. These results indicate that this region is specifically utilized by p57 in selectively inhibiting cyclin A or E/Cdk2 activities. Thus the 310 helix motif may confer a specific regulatory mechanism by which p57 differentially regulates Cdk2 and Cdk4 activities.

[1]  S. Elledge,et al.  Cdk inhibitors: on the threshold of checkpoints and development. , 1994, Current opinion in cell biology.

[2]  W. Sellers,et al.  Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors , 1996, Molecular and cellular biology.

[3]  J. Massagué,et al.  Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. , 1995, Genes & development.

[4]  M. Ewen,et al.  TGFβ inhibition of Cdk4 synthesis is linked to cell cycle arrest , 1993, Cell.

[5]  K. Nasmyth,et al.  Dams and sluices , 1993, Nature.

[6]  M. Dorée,et al.  p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity. , 1996, Oncogene.

[7]  S. Elledge,et al.  Inhibition of cyclin-dependent kinases by p21. , 1995, Molecular biology of the cell.

[8]  Anindya Dutta,et al.  Cyclin-binding motifs are essential for the function of p21CIP1 , 1996, Molecular and cellular biology.

[9]  J. R. Smith,et al.  Identification of the active region of the DNA synthesis inhibitory gene p21Sdi1/CIP1/WAF1. , 1995, The EMBO journal.

[10]  D N Shapiro,et al.  Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4 , 1995, Molecular and cellular biology.

[11]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[12]  C. Turck,et al.  Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit , 1993, Nature.

[13]  C. O'keefe,et al.  Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. , 1994, Genes & development.

[14]  David Beach,et al.  p21 is a universal inhibitor of cyclin kinases , 1993, Nature.

[15]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[16]  Tony Hunter,et al.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21 , 1994, Cell.

[17]  James M. Roberts,et al.  Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. , 1996, Genes & development.

[18]  C. Sherr G1 phase progression: Cycling on cue , 1994, Cell.

[19]  S. Elledge,et al.  p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. , 1995, Genes & development.

[20]  A. Levine,et al.  Analysis of wild-type and mutant p21WAF-1 gene activities , 1996, Molecular and cellular biology.

[21]  Philip D. Jeffrey,et al.  Crystal structure of the p27Kip1 cyclin-dependent-kinase inibitor bound to the cyclin A–Cdk2 complex , 1996, Nature.

[22]  J. LaBaer,et al.  New functional activities for the p21 family of CDK inhibitors. , 1997, Genes & development.

[23]  G. Hannon,et al.  p21-containing cyclin kinases exist in both active and inactive states. , 1994, Genes & development.

[24]  Gregory J. Hannon,et al.  pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest , 1994, Nature.

[25]  T. Hunter,et al.  Cyclins and cancer II: Cyclin D and CDK inhibitors come of age , 1994, Cell.

[26]  James M. Roberts,et al.  Cloning of p27 Kip1 , a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals , 1994, Cell.

[27]  M. Roussel,et al.  Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6 , 1995, Molecular and cellular biology.

[28]  David O. Morgan,et al.  Principles of CDK regulation , 1995, Nature.

[29]  J. Massagué,et al.  Differential Interaction of the Cyclin-dependent Kinase (Cdk) Inhibitor p27Kip1 with Cyclin A-Cdk2 and Cyclin D2-Cdk4* , 1997, The Journal of Biological Chemistry.